MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Gemcitabine synergizes with immune checkpoint inhibitors and overcomes resistance in a preclinical model and mesothelioma patients.

Clinical Cancer Research 2018 August 28 [Link]

Tallon de Lara P, Cecconi V, Hiltbrunner S, Yagita H, Friess M, Bode-Lesniewska B, Opitz I, Vrugt B, Weder W, Stolzmann P, Felley-Bosco E, Stahel RA, Tischler V, Britschgi C, Soldini D, van den Broek M, Curioni Fontecedro A

Abstract

Both comments and trackbacks are currently closed.